Literature DB >> 16569684

Increased urinary type II collagen helical and C telopeptide levels are independently associated with a rapidly destructive hip osteoarthritis.

P Garnero1, N Charni, F Juillet, T Conrozier, E Vignon.   

Abstract

OBJECTIVES: Biochemical markers reflecting the degradation of the type II collagen helical (Helix-II) and type II collagen C telopeptides (CTX-II) have been developed. AIM: To investigate the association of rapidly destructive hip osteoarthritis with urinary Helix-II and urinary CTX-II. PATIENTS AND METHODS: 12 patients (mean age 70 years) meeting the criteria for rapidly destructive hip osteoarthritis and 28 patients with slowly progressive hip osteoarthritis (mean age 63 years) defined as <0.20 mm joint space loss/year were included in a case-control study. In each patient, urinary Helix-II and CTX-II were measured at the end of the follow-up period, with retrospective evaluation of x rays.
RESULTS: Helix-II levels were 41% (p = 0.002) higher in the 40 patients with hip osteoarthritis than in 75 healthy controls. Increased Helix-II levels were associated with decreased minimum joint space width of the hip (r = -0.57, p = 0.001). Mean urinary Helix-II levels were 71% higher in rapidly destructive than in slowly progressive disease (mean (standard deviation (SD)) ng/mmol Cr: 396 (160) v 232 (118) ng/mmol; p = 0.002). When levels of Helix-II and CTX-II in the highest tertile were both included in a multivariate logistic regression model, high Helix-II level (OR; (95% CI) 5.73 (1.01 to 32.8)) after adjustment for age and body mass index and high CTX-II level (6.67 (1.14 to 39.0)) were, independently of each other, associated with a rapidly destructive disease.
CONCLUSION: Increased urinary Helix-II levels are associated with rapidly destructive hip osteoarthritis, independently of urinary CTX-II. Measurement of Helix-II, alone or in combination with CTX-II, could be useful for the clinical investigation of patients with hip osteoarthritis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16569684      PMCID: PMC1798449          DOI: 10.1136/ard.2006.052621

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  23 in total

1.  Association of baseline levels of urinary glucosyl-galactosyl-pyridinoline and type II collagen C-telopeptide with progression of joint destruction in patients with early rheumatoid arthritis.

Authors:  Patrick Garnero; Evelyne Gineyts; Stephan Christgau; Barbara Finck; Pierre D Delmas
Journal:  Arthritis Rheum       Date:  2002-01

2.  Analysis of collagenase-cleavage of type II collagen using a neoepitope ELISA.

Authors:  J T Downs; C L Lane; N B Nestor; T J McLellan; M A Kelly; G A Karam; P S Mezes; J P Pelletier; I G Otterness
Journal:  J Immunol Methods       Date:  2001-01-01       Impact factor: 2.303

3.  Collagen type II C-telopeptide fragments as an index of cartilage degradation.

Authors:  S Christgau; P Garnero; C Fledelius; C Moniz; M Ensig; E Gineyts; C Rosenquist; P Qvist
Journal:  Bone       Date:  2001-09       Impact factor: 4.398

4.  Uncoupling of type II collagen synthesis and degradation predicts progression of joint damage in patients with knee osteoarthritis.

Authors:  Patrick Garnero; Xavier Ayral; Jean-Charles Rousseau; S Christgau; Linda J Sandell; Maxime Dougados; Pierre D Delmas
Journal:  Arthritis Rheum       Date:  2002-10

5.  Association of baseline levels of markers of bone and cartilage degradation with long-term progression of joint damage in patients with early rheumatoid arthritis: the COBRA study.

Authors:  Patrick Garnero; Robert Landewé; Maarten Boers; Arco Verhoeven; Sjef Van Der Linden; Stephan Christgau; Désirée Van Der Heijde; Annelies Boonen; Piet Geusens
Journal:  Arthritis Rheum       Date:  2002-11

6.  Urinary type II collagen C-telopeptide levels are increased in patients with rapidly destructive hip osteoarthritis.

Authors:  P Garnero; T Conrozier; S Christgau; P Mathieu; P D Delmas; E Vignon
Journal:  Ann Rheum Dis       Date:  2003-10       Impact factor: 19.103

Review 7.  Biomarkers in osteoarthritis.

Authors:  Patrick Garnero; Pierre D Delmas
Journal:  Curr Opin Rheumatol       Date:  2003-09       Impact factor: 5.006

8.  The type II collagen fragments Helix-II and CTX-II reveal different enzymatic pathways of human cartilage collagen degradation.

Authors:  N Charni-Ben Tabassi; S Desmarais; A-C Bay-Jensen; J M Delaissé; M D Percival; P Garnero
Journal:  Osteoarthritis Cartilage       Date:  2008-04-09       Impact factor: 6.576

9.  Cartilage turnover assessed with a newly developed assay measuring collagen type II degradation products: influence of age, sex, menopause, hormone replacement therapy, and body mass index.

Authors:  U Mouritzen; S Christgau; H-J Lehmann; L B Tankó; C Christiansen
Journal:  Ann Rheum Dis       Date:  2003-04       Impact factor: 19.103

10.  The release of crosslinked peptides from type II collagen into human synovial fluid is increased soon after joint injury and in osteoarthritis.

Authors:  L Stefan Lohmander; Lynne M Atley; Terri A Pietka; David R Eyre
Journal:  Arthritis Rheum       Date:  2003-11
View more
  19 in total

1.  Bilateral chondrolysis of the hip following liver transplantation.

Authors:  Ofir Chechik; Samuel Dekel
Journal:  Skeletal Radiol       Date:  2008-12-03       Impact factor: 2.199

Review 2.  What is the utility of biomarkers for assessing the pathophysiology of hip osteoarthritis? A systematic review.

Authors:  Jeffrey J Nepple; Kayla M Thomason; Tonya W An; Marcie Harris-Hayes; John C Clohisy
Journal:  Clin Orthop Relat Res       Date:  2015-05       Impact factor: 4.176

3.  A case of rapidly destructive osteoarthritis of the hip with onset of less than six weeks.

Authors:  Elina Huerfano; Maria Bautista; Guillermo Bonilla; Mauricio Palau-Lazaro; Adolfo Llinás; Daniel Monsalvo
Journal:  J Clin Orthop Trauma       Date:  2017-02-24

4.  Injection of AAV2-BMP2 and AAV2-TIMP1 into the nucleus pulposus slows the course of intervertebral disc degeneration in an in vivo rabbit model.

Authors:  Steven K Leckie; Bernard P Bechara; Robert A Hartman; Gwendolyn A Sowa; Barrett I Woods; Joao P Coelho; William T Witt; Qing D Dong; Brent W Bowman; Kevin M Bell; Nam V Vo; Bing Wang; James D Kang
Journal:  Spine J       Date:  2011-10-22       Impact factor: 4.166

5.  Identification of progressors in osteoarthritis by combining biochemical and MRI-based markers.

Authors:  Erik B Dam; Marco Loog; Claus Christiansen; Inger Byrjalsen; Jenny Folkesson; Mads Nielsen; Arish A Qazi; Paola C Pettersen; Patrick Garnero; Morten A Karsdal
Journal:  Arthritis Res Ther       Date:  2009-07-24       Impact factor: 5.156

6.  Predictive validity of biochemical biomarkers in knee osteoarthritis: data from the FNIH OA Biomarkers Consortium.

Authors:  Virginia Byers Kraus; Jamie E Collins; David Hargrove; Elena Losina; Michael Nevitt; Jeffrey N Katz; Susanne X Wang; Linda J Sandell; Steven C Hoffmann; David J Hunter
Journal:  Ann Rheum Dis       Date:  2016-06-13       Impact factor: 19.103

7.  The Helix-II epitope: a cautionary tale from a cartilage biomarker based on an invalid collagen sequence.

Authors:  D R Eyre; M A Weis
Journal:  Osteoarthritis Cartilage       Date:  2009-03-05       Impact factor: 6.576

8.  Exosomes: roles and therapeutic potential in osteoarthritis.

Authors:  Zhenhong Ni; Siru Zhou; Song Li; Liang Kuang; Hangang Chen; Xiaoqing Luo; Junjie Ouyang; Mei He; Xiaolan Du; Lin Chen
Journal:  Bone Res       Date:  2020-06-19       Impact factor: 13.567

9.  Type II collagen fragment HELIX-II is a marker for early cartilage lesions but does not predict the progression of cartilage destruction in human knee joint synovial fluid.

Authors:  Xiaochun Wei; Kun Yin; Pengcui Li; Huan Wang; Juan Ding; Wangping Duan; Lei Wei
Journal:  Rheumatol Int       Date:  2012-01-12       Impact factor: 2.631

10.  Molecular and genetic advances in the regeneration of the intervertebral disc.

Authors:  Tristan Maerz; Harry Herkowitz; Kevin Baker
Journal:  Surg Neurol Int       Date:  2013-03-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.